CHF 2.4m · Other round · Healthtech · Plan-les-Ouates, Switzerland
Plan-les-Ouates-based Immitra Bio has completed an upsized CHF 2.4m pre-seed financing package to advance an in-vivo gene-editing platform and its lead programme, IB-003. The company said CHF 2.25m came from venture capital and private investors, with a further CHF 150k from non-dilutive sources. Backbone Ventures led the round and OCCIDENT co-led it, joined by Another VC, Kickfund, Venture Kick, Zürcher Kantonalbank, FONGIT, ETH Foundation and private investors. Company announcement
The proceeds are intended primarily for preclinical proof-of-concept studies of IB-003, which Immitra describes as a potential one-time treatment for an inherited anaemia. The company will also fund platform validation, further target discovery and additional pipeline work. These are development plans rather than evidence of clinical safety or efficacy; the programme remains preclinical.
Moving gene editing into the body
Many gene-editing and stem-cell therapies use an ex-vivo process: cells are removed from a patient, modified in a specialist facility and returned after conditioning. Immitra says its approach is designed to edit cells in vivo instead, avoiding cell collection, personalised manufacturing, chemotherapy-based conditioning and transplantation. It is also pursuing a mutation-agnostic strategy, intended to treat patients with the same disease even when their underlying mutations differ. Company platform
That design aims at a different commercial model. An off-the-shelf treatment could reduce the bespoke manufacturing and specialist-centre burden associated with patient-specific cell handling, making distribution less dependent on a tightly coordinated vein-to-vein workflow. But moving the edit directly into the body shifts the hardest questions toward delivery, targeting and control: the company must show that its system reaches the intended cells, edits them consistently and avoids harmful off-target effects.
The round buys the next evidence step
Immitra's digital target-identification platform is meant to find biological redundancies that can be used as alternative therapeutic targets, while its gene-editing technology executes the intervention. In principle, combining those layers could support more than one programme. For now, the financing is buying evidence around a lead asset and validation of the broader platform, not a finished therapeutic pipeline.
That makes the next value step unusually concrete. Successful preclinical proof-of-concept would provide data for candidate selection, delivery performance and disease reversal in relevant models. Weak or inconsistent results would force changes before clinical development. The CHF 150k non-dilutive component slightly extends the package, but the central test remains scientific: whether a mutation-agnostic, in-vivo approach can produce sufficiently precise and reproducible results to justify the much larger capital required for toxicology, manufacturing and human studies.
